Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Garattini

Bertelé

Banzi

. Placebo? No thanks, it might be bad for me! Eur J Clin Pharmacol 2013; 69: 711–714.

Cohen

Barkoff

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol 2014; 13: 545–556. http://dx.doi.org/10.1016/S1474–4422(14)70049–3

Giovannoni

Gold

Selmaj

. Daclizumab high-yield process in relapsing–remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial. Lancet Neurol 2014; 13: 472–481.

Gold

Giovannoni

Selmaj

. Daclizumab high-yield process in relapsing–remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 2167–2175.

Edan

Kappos

Montalban

. Long-term impact of interferon beta-1b in patients with CIS: 8-Year follow-up of BENEFIT. J Neurol Neurosurg Psych 2013. [Epub ahead of print; doi: 10.1136/jnnp-2013–306222].

World Medical Association. The Declaration of Helsinki, http://wma.net/en/30publications/10policies/b3/ (2013, accessed 22 May 2014).